噻托溴胺粉吸入剂治疗稳定期慢性阻塞性肺疾病的临床观察

Clinical observation of tiotropium powder for inhalation in stable chronic obstructive pulmonary disease

目的:观察噻托溴胺粉吸入剂在治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法:将我院呼吸科门诊就诊的确诊为稳定期COPD患者142例,随机分为治疗组和对照组。对照组给予常规解痉、平喘、祛痰等治疗,治疗组在此基础上给予吸入噻托溴胺,(规格18ug/粒)1粒/日,疗程24周,分别对2组患者治疗前后的症状缓解,急性发作频率,肺功能指标进行观察对比,评价药物疗效。结果:治疗组患者治疗前后症状明显改善,两组疗效比较差异有统计学意义(P<0.01);对照组无明显变化。治疗组治疗前后FEV1,FEV1%预计值,FEV1/FVC%有显著改善,差异有统计学意义(P<0.05);而对照组各指标差异无统计学意义。治疗组患者急性发作频率明显减少,有统计学意义(P<0.05),对照组无明显变化。结论:噻托溴胺粉吸入剂治疗稳定期慢性阻塞性肺疾病(COPD)患者,能有效改善症状,改善肺功能,减少急性加重频率,值得临床上推广。

Objective：To observe the effects of tiotropium powder for inhalation in the treatment of stable chronic obstructive pulmonary disease（COPD）.Meth-ods：142 cases outpatient with diagnosis of stable COPD were randomly divided into treatment group and control group.The control group received conventional treatment,the treatment group was given inhaled tiotropium powder beside conventional treatment,the dosage is one inhalation（18ug）each time,one per day,period of treatment is 24 weeks.The symptom,frequency of acute attack and index of pulmonary function of two groups were contrasted to evaluate the curative effect.Results：The symptom were obviously improved in treatment group,the difference between two groups has statistic significance（P 0.01）.The FEV1,FEV1 /PREDICTION%,FEVI/FEVI% in the treatment group were improved obviously after treatment（P 0.05）,but the indexes before and after treatment have no obvious difference in control group.The frequency of acute attack in treatment group has decreased obviously after treatment（P 0.05）,this index has no obvious change in control group before and after treat-ment.Conclusion：Tiotropium powder for inhalation in the treatment of stable COPD can obviously improve symptom,ameliorate pulmonary function,reduce the frequency of acute attack.